IS6443A - Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar - Google Patents

Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar

Info

Publication number
IS6443A
IS6443A IS6443A IS6443A IS6443A IS 6443 A IS6443 A IS 6443A IS 6443 A IS6443 A IS 6443A IS 6443 A IS6443 A IS 6443A IS 6443 A IS6443 A IS 6443A
Authority
IS
Iceland
Prior art keywords
pyrido
pyrimidine
diamine
kinase inhibitors
kinase
Prior art date
Application number
IS6443A
Other languages
English (en)
Icelandic (is)
Inventor
John Booth Richard
Myra Dobrusin Ellen
Prasad Venkata Nagendra Josyula Vara
Joseph Mcnamara Dennis
Laurence Toogood Peter
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS6443A publication Critical patent/IS6443A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
IS6443A 2000-01-25 2002-06-25 Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar IS6443A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
PCT/IB2001/000069 WO2001055147A1 (en) 2000-01-25 2001-01-23 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
IS6443A true IS6443A (is) 2002-06-25

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6443A IS6443A (is) 2000-01-25 2002-06-25 Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar

Country Status (34)

Country Link
EP (1) EP1254137A1 (es)
JP (1) JP4047010B2 (es)
KR (1) KR20020065939A (es)
CN (1) CN1395578A (es)
AP (1) AP2002002586A0 (es)
AR (1) AR030044A1 (es)
AU (1) AU2542501A (es)
BG (1) BG106850A (es)
BR (1) BR0107751A (es)
CA (1) CA2397961C (es)
CO (1) CO5261549A1 (es)
CR (1) CR6706A (es)
CZ (1) CZ20022475A3 (es)
DZ (1) DZ3266A1 (es)
EA (1) EA200200643A1 (es)
EE (1) EE200200405A (es)
GT (1) GT200100016A (es)
HN (1) HN2001000013A (es)
HU (1) HUP0204141A3 (es)
IL (1) IL150545A0 (es)
IS (1) IS6443A (es)
MA (1) MA26868A1 (es)
MX (1) MXPA02007221A (es)
NO (1) NO20023527L (es)
OA (1) OA12161A (es)
PA (1) PA8510701A1 (es)
PE (1) PE20011066A1 (es)
PL (1) PL356802A1 (es)
SK (1) SK10632002A3 (es)
SV (1) SV2002000294A (es)
TN (1) TNSN01014A1 (es)
WO (1) WO2001055147A1 (es)
YU (1) YU50402A (es)
ZA (1) ZA200205879B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
MXPA04010267A (es) 2002-04-19 2005-02-03 Smithkline Beecham Corp Compuestos novedosos.
EA200500721A1 (ru) * 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
JP2008518883A (ja) * 2004-09-21 2008-06-05 エフ．ホフマン−ラ ロシュ アーゲー タンパク質キナーゼ阻害剤として有用な６−（２−アルキル−フェニル）−ピリド［２，３−ｄ］ピリミジン
MY145343A (en) 2005-03-25 2012-01-31 Glaxo Group Ltd Novel compounds
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
US20080096905A1 (en) 2005-03-25 2008-04-24 Glaxo Group Limited Process For Preparing Pyrido[2,3-D]Pyrimidin-7-One And 3,4-Dihydropyrimido{4,5-D}Pyrimidin-2(1H)-One Derivatives
FR2887882B1 (fr) * 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
ATE449097T1 (de) * 2005-07-21 2009-12-15 Hoffmann La Roche Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
ES2351939T3 (es) 2005-08-09 2011-02-14 Irm Llc Compuestos y composiciones como inhibidores de proteínas cinasas.
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
AU2009321867B2 (en) * 2008-12-01 2015-12-10 Merck Patent Gmbh 2,5-Diamino-substituted pyrido[4,3-d]pyrimidines as autotaxin inhibitors against cancer
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
ES2817448T3 (es) 2013-03-14 2021-04-07 Icahn School Med Mount Sinai Compuestos de pirimidina como inhibidores de quinasas
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2191188C2 (ru) * 1994-11-14 2002-10-20 Варнер-Ламберт Компани Производные 6-арилпиридо[2,3-d]-пиримидины и -нафтиридины, фармацевтическая композиция, обладающая ингибирующим действием клеточной пролиферации, вызываемой протеиновой тирозинкиназой, и способ ингибирования клеточной пролиферации
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
EE200000706A (et) * 1998-05-26 2002-06-17 Warner-Lambert Company Bitsüklilised pürimidiinid ja bitsüklilised 3,4-dihüdropürimidiinid kui rakkude proliferatsiooni inhibiitorid

Also Published As

Publication number Publication date
NO20023527D0 (no) 2002-07-24
PE20011066A1 (es) 2001-10-22
NO20023527L (no) 2002-09-10
BR0107751A (pt) 2002-11-12
JP4047010B2 (ja) 2008-02-13
DZ3266A1 (fr) 2001-08-02
GT200100016A (es) 2001-10-19
EE200200405A (et) 2003-12-15
AP2002002586A0 (en) 2002-09-30
TNSN01014A1 (fr) 2005-11-10
CR6706A (es) 2005-04-04
MA26868A1 (fr) 2004-12-20
JP2003523357A (ja) 2003-08-05
EA200200643A1 (ru) 2002-12-26
KR20020065939A (ko) 2002-08-14
SK10632002A3 (sk) 2003-06-03
EP1254137A1 (en) 2002-11-06
CN1395578A (zh) 2003-02-05
BG106850A (bg) 2003-02-28
IL150545A0 (en) 2003-02-12
CA2397961C (en) 2008-08-26
HN2001000013A (es) 2001-06-18
CA2397961A1 (en) 2001-08-02
ZA200205879B (en) 2003-09-29
PA8510701A1 (es) 2002-12-11
CZ20022475A3 (cs) 2003-03-12
YU50402A (sh) 2005-11-28
PL356802A1 (en) 2004-07-12
AR030044A1 (es) 2003-08-13
CO5261549A1 (es) 2003-03-31
HUP0204141A2 (hu) 2003-04-28
HUP0204141A3 (en) 2005-03-29
MXPA02007221A (es) 2002-11-29
SV2002000294A (es) 2002-07-16
OA12161A (en) 2006-05-08
AU2542501A (en) 2001-08-07
WO2001055147A1 (en) 2001-08-02

Similar Documents

Publication Publication Date Title
IS6443A (is) Pýridó[2,3-d]pýrimidín-2,7-díamín kínasa latar
PL358271A1 (pl) 5-alkilopirydo[2,3-D]pirymidyny jako inhibitory kinazy tyrozyny
DK1416935T3 (da) 4-Amino-6-phenyl-pyrrolo[2,3-d]pyrimidinderivater
DK1235830T3 (da) Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
DE60016615D1 (de) Pyrazolo[4,3-d]pyrimidinderivate
DE60207241D1 (de) 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate
IL181957A0 (en) Pyrimidine-4-one derivatives as ldl-pla2 inhibitors
DE60130463D1 (de) Pyrimidin-derivate
MA26819A1 (fr) Pteridinones servant d' inhibiteurs de kinases.
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
NO20026247D0 (no) 5-aminoalkyl-pyrazolo[4,3-d]pyrimidiner med en fosfodiesterase V-inhiberende virkning
DK1294729T3 (da) 2-aminoalkyl-thieno[2,3-d]pyrimidiner
PT1326866E (pt) 3,4-di-hidropirido[1,2-a]pirimidinas substituidas
ZA200206528B (en) Pyrimidine-4-one derivatives as LDL-PLA2 inhibitors.
DK1326866T3 (da) Substituerede 3,4-dihydro-pyrido[1,2-a]pyrimidiner